AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial
AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato-DXd to the investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive,
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan (Dato-DXd) is a new form of cancer treatment,
precisionmedicineonline3h
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd Benefit Despite Overall Survival Miss
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
MM&M3d
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
FiercePharma3d
Daiichi, AZ's first Enhertu DTC campaign kicks off during Thursday Night Football
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Astra, Daiichi Drop on Mixed Lung Cancer Drug Trial Result
Daiichi Sankyo Co. shares drop as much as 10.4% on Tuesday, the most since Aug. 5, after its lung cancer drug with ...
pharmaphorum4d
Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia
NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
FiercePharma3d
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...